Analyzing Next-Generation Sequencing Data
June 6th – June 17th, 2011
Kellogg Biological Station, Michigan State University
Instructors: Dr. C. Titus Brown, Dr. Ian Dworkin, and Dr. Istvan Albert.
Applications must be received by March 25th for full consideration.
More information and application link here:
This intensive two week summer course will introduce students with a strong
biology background to the practice of analyzing short-read sequencing data from
Roche 454, Illumina GA2, ABI SOLiD, Pacific Biosciences, and other next-gen
platforms. The first week will introduce students to computational thinking and
large-scale data analysis on UNIX platforms. The second week will focus on
mapping, assembly, and analysis of short-read data for resequencing, ChIP-seq,
No prior programming experience is required, although familiarity with some
programming concepts is helpful, and bravery in the face of the unknown is
necessary. 2 years or more of graduate school in a biological science is
Students will gain practical experience in:
* Python and bash shell scripting
* cloud computing/Amazon EC2
* basic software installation on UNIX
* installing and running maq, bowtie, and velvet
* querying mappings and evaluating assemblies
Materials from last year’s course are available at http://ged.msu.edu/angus/
under a Creative Commons/use+reuse license.
Ian Dworkin firstname.lastname@example.org
The National Human Genome Research Institute said this week that it has chosen Daniel Kastner to be its new scientific director. Kastner, who will join NHGRI in October, currently is clinical director and director of translational research at the National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Former Genome Canada President and CEO Martin Godbout has been appointed chairman of MethylGene‘s board of directors. Godbout, who held the top post at Genome Canada between 2000 and 2009, has served as a member of MethylGene’s board since 2002. He also has been senior VP of BioCapital and president and GM of Société Innovatech Québec.
Emergent Biosolutions has appointed former National Cancer Institute Director John Niederhuber to serve on its board of directors.
Niederhuber was director at NCI from 2005 to 2010, and he recently joined Inova Health System as executive VP and CEO of the Inova Institute for Translational Research and Personalized Medicine. He also still works as an adjunct investigator at NCI’s Center for Cancer Research.